Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.

Demaria, Olivier; Carvelli, Julien; Batista, Luciana; Thibult, Marie-Laure; Morel, Ariane; André, Pascale; Morel, Yannis; Vély, Frederic; Vivier, Eric

Demaria, Olivier; Carvelli, Julien; Batista, Luciana; Thibult, Marie-Laure; Morel, Ariane; André, Pascale; Morel, Yannis; Vély, Frederic; Vivier, Eric.

Demaria O; Innate Pharma, 117 avenue de Luminy, Marseille, 13009, France. olivier.demaria@innate-pharma.fr.
Carvelli J; Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Réanimation des Urgences, Marseille, 13005, France.
Batista L; Innate Pharma, 117 avenue de Luminy, Marseille, 13009, France.
Thibult ML; Innate Pharma, 117 avenue de Luminy, Marseille, 13009, France.
Morel A; Innate Pharma, 117 avenue de Luminy, Marseille, 13009, France.
André P; Innate Pharma, 117 avenue de Luminy, Marseille, 13009, France.
Morel Y; Innate Pharma, 117 avenue de Luminy, Marseille, 13009, France.
Vély F; Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, 13009, France.
Vivier E; Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Immunology, Marseille Immunopole, Marseille, 13005, France.

Cell Mol Immunol ; 17(9): 995-997, 2020 09.

Article in English | MEDLINE | ID: covidwho-625131

Subject(s)

Betacoronavirus/pathogenicity; Coronavirus Infections/immunology; Molecular Targeted Therapy/methods; Pneumonia, Viral/immunology; Pneumonia/immunology; Severe Acute Respiratory Syndrome/immunology; Antiviral Agents/therapeutic use; Apyrase/antagonists & inhibitors; Apyrase/genetics; Apyrase/immunology; B-Lymphocytes/immunology; B-Lymphocytes/pathology; B7-H1 Antigen/antagonists & inhibitors; B7-H1 Antigen/genetics; B7-H1 Antigen/immunology; Betacoronavirus/immunology; COVID-19; Case-Control Studies; Coronavirus Infections/drug therapy; Coronavirus Infections/genetics; Coronavirus Infections/virology; Gene Expression/drug effects; Humans; Immunologic Factors/therapeutic use; Killer Cells, Natural/drug effects; Killer Cells, Natural/immunology; Killer Cells, Natural/pathology; NK Cell Lectin-Like Receptor Subfamily C/antagonists & inhibitors; NK Cell Lectin-Like Receptor Subfamily C/genetics; NK Cell Lectin-Like Receptor Subfamily C/immunology; Pandemics; Pneumonia/drug therapy; Pneumonia/genetics; Pneumonia/virology; Pneumonia, Viral/drug therapy; Pneumonia, Viral/genetics; Pneumonia, Viral/virology; Programmed Cell Death 1 Receptor/antagonists & inhibitors; Programmed Cell Death 1 Receptor/genetics; Programmed Cell Death 1 Receptor/immunology; SARS-CoV-2; Severe Acute Respiratory Syndrome/drug therapy; Severe Acute Respiratory Syndrome/genetics; Severe Acute Respiratory Syndrome/virology; T-Lymphocyte Subsets/immunology; T-Lymphocyte Subsets/pathology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia / Pneumonia, Viral / Coronavirus Infections / Severe Acute Respiratory Syndrome / Molecular Targeted Therapy / Betacoronavirus Type of study: Observational study Language: English Journal: Cell Mol Immunol Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: S41423-020-0493-9

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google